After languishing for almost two years,Tanox Biosystems Inc.'s anti-HIV monoclonal antibodies have been returned to the company by partner Ciba-Geigy Ltd.
Ciba completed a Phase I/II Swiss trial in 12 late-stage AIDS patients in October 1991 and reported on the safety of the lead compound, AIDS-439, at the 1992 AIDS meeting in Amsterdam. But according to David Anderson, executive vice president and COO, a reorganization of Ciba's worldwide R&D resulted in the departure of the product's champion and a